Alphatec Holdings, Inc. (NASDAQ:ATEC) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have received a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $17.89.

ATEC has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Alphatec in a research report on Monday, April 14th. Needham & Company LLC reissued a “buy” rating and issued a $16.00 price target on shares of Alphatec in a research note on Friday. Barclays lifted their price objective on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, January 22nd. Piper Sandler restated an “overweight” rating and issued a $15.00 target price (up previously from $13.00) on shares of Alphatec in a research note on Friday. Finally, StockNews.com upgraded Alphatec from a “sell” rating to a “hold” rating in a research report on Friday, February 28th.

Insider Activity at Alphatec

In other news, EVP David Sponsel sold 36,256 shares of Alphatec stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $11.42, for a total value of $414,043.52. Following the completion of the transaction, the executive vice president now owns 735,074 shares of the company’s stock, valued at $8,394,545.08. The trade was a 4.70 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Scott Lish sold 27,453 shares of the company’s stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $11.49, for a total transaction of $315,434.97. Following the completion of the transaction, the chief operating officer now owns 867,677 shares in the company, valued at approximately $9,969,608.73. The trade was a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 222,113 shares of company stock valued at $2,519,725 in the last 90 days. Corporate insiders own 22.80% of the company’s stock.

Hedge Funds Weigh In On Alphatec

Hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its holdings in shares of Alphatec by 38,433.3% in the 1st quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company’s stock worth $228,000 after purchasing an additional 2,306 shares in the last quarter. Comerica Bank increased its holdings in Alphatec by 66.8% in the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock worth $29,000 after buying an additional 1,248 shares in the last quarter. R Squared Ltd purchased a new position in Alphatec in the 4th quarter worth about $29,000. Nisa Investment Advisors LLC lifted its stake in Alphatec by 973.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock valued at $43,000 after acquiring an additional 4,234 shares during the period. Finally, Larson Financial Group LLC purchased a new stake in shares of Alphatec during the 1st quarter valued at about $54,000. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Alphatec Price Performance

ATEC stock opened at $12.00 on Friday. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The firm’s 50-day moving average price is $10.46 and its two-hundred day moving average price is $9.86. The stock has a market capitalization of $1.75 billion, a price-to-earnings ratio of -9.38 and a beta of 1.20. Alphatec has a 12-month low of $4.88 and a 12-month high of $13.79.

Alphatec (NASDAQ:ATEC) last released its quarterly earnings results on Thursday, May 1st. The medical technology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.23). The business had revenue of $169.18 million for the quarter, compared to the consensus estimate of $167.57 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The company’s revenue for the quarter was up 22.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.34) EPS. As a group, equities analysts predict that Alphatec will post -1.08 earnings per share for the current year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.